U.S. officials have approved Boston Scientific’s (NYSE:BSX) Infinion-branded lead to be used with its new rechargeable chronic pain management device.
The company on Thursday that the FDA-approved lead will be used in its Precision Plus Spinal Cord Stimulator (SCS) system, which is the first rechargeable SCS on the market.
The SCS lead is designed to deliver up to 16 electrical pulses from an implantable pulse generator to the spinal cord to mask pain signals to the brain. Previously, these leads have offered a maximum of just eight stimulating contracts.
Chronic pain impacts more than 75 million Americans, according to the American Pain Foundation.
By offering double the number of contracts, Boston Scientific notes the lead can “offer more coverage of the spinal cord for the management of chronic pain.”